Ziprasidone Hydrochloride Monohydrate is an atypical antipsychotic medication primarily used as an active pharmaceutical ingredient (API) in the treatment of schizophrenia and bipolar disorder. It functions by antagonizing dopamine D2 and serotonin 5-HT2A receptors, helping to restore neurotransmitter balance in the brain and alleviate symptoms such as hallucinations, delusions, and mood swings. This high-purity compound (≥98% by HPLC) is suitable for pharmaceutical research, formulation development, or as a reference standard. It is not intended for direct patient use without proper processing and regulatory approval. Professional handling and safety precautions are required due to potential hazards.